Evidence map›Paper›PMID 31993106›Full record

ReviewInternational journal of physiology, pathophysiology and pharmacology2019

CD200-CD200R signaling and diseases: a potential therapeutic target?

Conelius Ngwa, Fudong Liu

Open access · greenAbstract readReview
In one paragraph

Review in International journal of physiology, pathophysiology and pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Frontiers in pharmacology · 2025
    Review
  7. Article
  8. Immune Checkpoints in Endometriosis-A New Insight in the Pathogenesis.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Conelius NgwaDepartment of Neurology, The University of Texas Health Science Center at Houston McGovern Medical School Houston, TX 77030, USA.
Fudong LiuDepartment of Neurology, The University of Texas Health Science Center at Houston McGovern Medical School Houston, TX 77030, USA.
The University of Texas Health Science Center · US

Funding

Contribution of the X Chromosome to Sex Differences in StrokeR01NS108779 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LIU, FUDONG, MCCULLOUGH, LOUISE D. · 2018 to 2022
$2.7M
IRF5-IRF4 Regulatory Axis: A new Target for StrokeR01NS093042 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LIU, FUDONG · 2015 to 2019
$1.7M
NINDS NIH HHS R01 NS093042NINDS NIH HHS R01 NS108779
6 · The paper itself

Abstract

CD200 and its receptor, CD200R, constitutes an endogenous inhibitory signaling, and is being increasingly recognized in studies of various central nervous system (CNS) disorders. Emerging data have demonstrated that neuronal CD200 binds to CD200R to modulate immune responses to pathogenic stimuli. However, on which component of the immune response that CD200-CD200R signaling acts is not well understood. In this review, we focused on cellular expression of the signaling, the effects on immune cell activation, and the function in pathological procedures of neurodegenerative diseases, in both clinical and experimental disease models. Essential functions of CD200-CD200R interaction and the treatment relevance have been elaborated. Immune responses to diseases under the control of CD200-CD200R axis were also discussed in the review.

Indexed as

BrainCD200CD200Rimmune responsesneuron

Identifiers

PMID31993106
PMCPMC6971504
OpenAlexW3003185605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.